US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Glaukos Corp

us-stock
To Invest in {{usstockname}}
us-stock
$107 0.0131(1.31%) GKOS at 04 Dec 2025 04:33 PM Medical Devices
Lowest Today 106.29
Highest Today 109.24
Today’s Open 106.5
Prev. Close 106.07
52 Week High 163.71
52 Week Low 73.16
Day’s Range: Low 106.29 High 109.24
52-Week Range: Low 73.16 High 163.71
1 day return -
1 Week return +1.05
1 month return +25.04
3 month return +19.26
6 month return +18.18
1 year return -22.24
3 year return +134.13
5 year return +52.96
10 year return -

Institutional Holdings

BlackRock Inc 15.21

FMR Inc 11.05

Vanguard Group Inc 10.66

iShares Core S&P Small-Cap ETF 5.92

Wellington Management Company LLP 5.66

State Street Corp 3.64

Ameriprise Financial Inc 3.49

PRIMECAP Management Company 3.19

Vanguard Total Stock Mkt Idx Inv 3.00

iShares Russell 2000 ETF 2.35

Geode Capital Management, LLC 2.32

Vanguard Small Cap Index 2.30

AllianceBernstein L.P. 2.18

Westfield Capital Management Company, L.P. 2.04

Brown Capital Management, LLC 1.99

William Blair Investment Management, LLC 1.98

American Funds SMALLCAP World A 1.91

HHG PLC 1.90

Holocene Advisors, LP 1.82

Vanguard Health Care Inv 1.78

Amvescap Plc. 1.74

PRIMECAP Odyssey Aggressive Growth 1.64

Capital World Investors 1.48

Vanguard Explorer Inv 1.41

Vanguard Small Cap Growth Index Inv 1.29

NORGES BANK 1.29

Point72 Asset Management, L.P. 1.25

Gilder Gagnon Howe & CO LLC 1.22

Charles Schwab Investment Management Inc 1.22

Vanguard Capital Opportunity Inv 1.22

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Janus Henderson Triton D 1.06

Janus Henderson US SMID Cap Growth 1.06

Janus Henderson US SMID Cap Growth MA 1.06

Fidelity Small Cap Index 0.98

Columbia Small Cap Growth 0.89

Columbia Small Cap Growth Inst 0.89

SPDR® Portfolio S&P 600™ Sm Cap ETF 0.88

iShares S&P Small-Cap 600 Growth ETF 0.86

iShares Russell 2000 Growth ETF 0.86

Market Status

Strong Buy: 9

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 1

Fundamentals

Market Cap 6092.10 M

PB Ratio 7.9195

PE Ratio 0.0

Enterprise Value 5925.00 M

Total Assets 974.76 M

Volume 763065

Company Financials

Annual Revenue FY24:383481000 383.5M, FY23:303573000 303.6M, FY22:282862000 282.9M, FY21:294011000 294.0M, FY20:224959000 225.0M

Annual Profit FY24:289454000 289.5M, FY23:229667000 229.7M, FY22:213883000 213.9M, FY21:227384000 227.4M, FY20:133240000 133.2M

Annual Net worth FY24:-146372000 -146.4M, FY23:-129342000 -129.3M, FY22:-99195000 -99.2M, FY21:-49593000 -49.6M, FY20:-120348000 -120.3M

Quarterly Revenue Q3/2025:133537000 133.5M, Q2/2025:124120000 124.1M, Q1/2025:106664000 106.7M, Q3/2024:96670000 96.7M, Q2/2024:95690000 95.7M

Quarterly Profit Q3/2025:104706000 104.7M, Q2/2025:97224000 97.2M, Q1/2025:82348000 82.3M, Q3/2024:74086000 74.1M, Q2/2024:73140000 73.1M

Quarterly Net worth Q3/2025:-16231000 -16.2M, Q2/2025:-19657000 -19.7M, Q1/2025:-18146000 -18.1M, Q3/2024:-21409000 -21.4M, Q2/2024:-50545000 -50.5M

Fund house & investment objective

Company Information Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Organisation Medical Devices

Employees 995

Industry Medical Devices

CEO Mr. Thomas William Burns

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right